ELAN FIT

Lancet Healthy Longev. 2024 May 14:S2666-7568(24)00048-5. PMID: 38759667

Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial

Joël Guigay 1, Hervé Le Caer 2, François-Régis Ferrand 3, Lionel Geoffrois 4, Esma Saada-Bouzid 5, Jérôme Fayette 6, Christian Sire 7, Didier Cupissol 8, Emmanuel Blot 9, Pierre Guillet 10, Julien Pavillet 11, Laurence Bozec 12, Olivier Capitain 13, Frédéric Rolland 14, Philippe Debourdeau 15, Yoann Pointreau 16, Claire Falandry 17, Stéphane Lopez 18, Alexandre Coutte 19, Thierry Chatellier 20, Pierre Dalloz 21, Cécile Ortholan 22, Cécile Michel 23, Benjamin Lacas 24, Nadir Cheurfa 24, Dominique Schwob 24, Jean Bourhis 25, Cécile Mertens 26, Anne Aupérin 24; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups, and GORTEC